A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Trial Profile

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2018

At a glance

  • Drugs Axicabtagene ciloleucel (Primary)
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms ZUMA-3
  • Sponsors Kite Pharma
  • Most Recent Events

    • 17 Jun 2018 Results from patients treated with prior Blinatumomab (n=29) presented at the 23rd Congress of the European Haematology Association
    • 05 Jun 2018 Results (data cut off: Jul 31, 2017) reporting responses to KTE-C19 in patients who received prior blinatumomab presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 04 Jun 2018 Results presented in the Kite Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top